This article provides a brief overview and analysis of generic test content, examining its fundamental characteristics and potential implications.
Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.
The Furious's jaw-dropping action scenes are so ferocious and inventive that they leave you gasping for breath, commends Sreeju Sudhakaran.
Instant messaging platform Telegram has been restored in India after a week-long government ban, imposed due to its alleged role in circulating leaked NEET examination papers, expired. The Delhi High Court had upheld the ban as lawful and necessary.
Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net profit falling 55 per cent to Rs 554.6 crore, missing consensus estimates. Despite strong growth in India and Africa, a significant decline in North American sales impacted overall performance, with the company now focusing on new product launches and regulatory filings to drive future gains.
Dhruv Sarja's KD: The Devil attempts to deliver a grounded action experience but ultimately succumbs to a loud, generic gangster narrative, muddled storytelling, and excessive theatrics, sighs Arjun Menon.
The NTA has also confirmed that the upcoming re-examination, scheduled for June 21, 2026, will be conducted entirely free of cost for all previously registered candidates, funded fully through the agency's internal reserves.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
The Central Information Commission (CIC) has directed the Income Tax Department to disclose 'generic details of the net taxable income/gross income' of an estranged husband to his wife for pursuing maintenance proceedings. The commission stated that such information cannot be denied on privacy grounds in matrimonial disputes.
'Infertility and reproductive health challenges, much like other chronic conditions, are rising globally.'
Ramayana, which is being mounted as a two-part cinematic event, will soar. The music, visuals, technical finesse and the promise of strong performances not just tease a film, it teases a grand experience, notes Mayur Sanap.
10 stocks from the Nifty 200 index that offer good growth potential and scope to deliver decent returns from current levels, based on brokerage estimates.
Both countries commit to provide each other preferential market access in sectors of respective interest on a sustained basis
US and India will promptly implement this framework and work towards finalising the interim agreement with a view to concluding a mutually beneficial bilateral trade agreement.
Most first-time investors may be better served by diversified options such as flexicap or multi-cap funds, which already hold pharma and healthcare stocks.
The agreement addresses non-tariff barriers and promotes increased trade in technology products and cooperation between the two countries.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Iran is fighting a different war: Older, slower, and in some ways more dangerous. Iran doesn't need to shoot down an F/A-18. It only needs to make the Strait of Hormuz feel dangerous long enough for insurance markets, shipping companies, and oil futures traders to do the rest. Prem Panicker continues his must-read daily blog on the war in the Middle East.
The Nifty IT index hit a more than nine-month low, trading at its weakest level since April 17, 2025.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
The fiscal tilt towards capex benefits companies in investment-related sectors like capital goods, defence equipment, engineering & construction and metal & mining. The planned cut in revenue expenditure will weigh on companies in consumption sectors like FMCG, consumer durables and retail.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
'Indian markets may underperform global peers for the next two quarters.' 'But beyond that, India should catch up and resume its long-term growth path.'
If it wasn't so violent, there would have been a few unintended laughs in Baaghi 4, but this one has not a shred of humour amidst the nonstop mayhem, observes Deepa Gahlot.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.
Infosys has laid off 195 trainees for failing internal assessments, according to emails sent by India's second largest IT services firm. It is the company's third layoff of trainees this year. As many as 320 trainees were dropped in February on similar grounds and 240 earlier this month.
At the end of the day, this isn't about choosing between EMIs and SIPs. It's about choosing your path to financial freedom.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries, has clawed back nearly half of those losses. Recent acquisitions, a favourable court ruling in the case of the hair loss drug Leqselvi, an edge over peers owing to its specialty portfolio, and a diversified global presence have supported the recovery.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
While most investors brush off NFOs like spam, some of them offer solid opportunities, especially when you know what to look for. So let's clear the confusion around NFOs and figure out when they're worth your money, and when they're not.
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
The Securities and Exchange Board of India (Sebi), in a circular dated April 11, 2025, warned investors about rising fraud and manipulation linked to the securities market on social media platforms.
The current situation in Kerala politics is perhaps best described as a case of the state's traditional two front politics now seeing a third front (the BJP) muscling in with the potential outcome being either a messy three front affair or a renewed endorsement of the two front pattern but with one of the old fronts compromised or quashed, observes Shyam G Menon.
By staying informed and focusing on legitimate job openings, candidates can navigate the job market more effectively and safeguard their career aspirations.
Around six weeks ago, Sun Pharmaceutical Industries, India's largest drugmaker, suffered a setback, which led to a selloff in the share. The US District Court of New Jersey granted Incyte's request for a preliminary injunction against Sun Pharma's launch of Leqselvi, a drug that treats alopecia.
Brokerages expect a further slowdown in Indian firms' revenue and earnings growth in Q4FY25, following low single-digit growth in the preceding three quarters, as factors like weak consumer demand and credit growth linger on.
